Advanced Therapy Medical Products (ATMPs) are in high demand because of their capacity to give tailored treatment that addresses the fundamental cause rather than treating symptoms. The global market size for ATMPs is predicted to reach USD 21.2 billion by 2028, representing a 13.2 percent CAGR over the next seven years, thanks to the revolutionary benefit it gives that is not offered by traditional treatments.
Advanced Therapy Medicinal Products in humans may pose distinct risks to patients and third parties. These dangers are influenced by a number of risk factors relating to the ATMP’s purity, biological activity, and application. The ‘Risk based approach’ describes a flexible way to handle and evaluate potential hazards associated with the clinical use of ATMPs.
In this video whitepaper, we will discuss the following topics:
- Understanding the concept of ATMP
- Risk based approach to ATMP
- How to integrate EQMS in Advanced Therapies Manufacturing
- And more